According to a newly published market research report by 24LifeSciences, global oral typhoid vaccine market was valued at USD 34.2 million in 2026 and is projected to reach USD 47.3 million by 2034, growing at a compound annual growth rate (CAGR) of 4.9% during the forecast period 2026–2034.

Oral typhoid vaccines are specialized pharmaceutical products designed to provide immunity against typhoid fever, a serious and often fatal bacterial infection caused by Salmonella Typhi. These vaccines are formulated as live-attenuated bacterial suspensions that are administered orally, stimulating both systemic and mucosal immune responses. This dual mechanism offers distinct advantages over injectable alternatives, particularly in pediatric and mass vaccination scenarios where needle-based administration presents logistical challenges. Their established efficacy in preventing enteric fever continues to underpin their importance in travel medicine and public health initiatives.

Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/4393/oral-typhoid-vaccine-market